Skip to main content
Free trial

Ask AI to review this stock

Copy the prompt to get recent events, historical reactions, and a short research brief.

Tell your AI:

Help me set up FinLab and analyze CPRX Catalyst Pharmaceuticals, Inc.. Please read: https://finlab.finance/en/setup?stock=CPRX

No install, open FinLab Studio

CPRX

Catalyst Pharmaceuticals, Inc. Healthcare As of 2026-08-03 Updated daily after market close

strong quality, premium valuation.

1 active signal
Top-quintile 6-month momentum
This page refreshes daily after the close. Add Catalyst Pharmaceuticals, Inc. to your watchlist to track signal changes on your next visit.
Valuation 41Quality 88Growth 65Momentum 50Risk / liquidity 89

Is Catalyst Pharmaceuticals, Inc. a buy? Fundamentals and valuation first

  • Quality is top-tier. Operating margin ranks above roughly 91% of the liquid US common-stock universe. TTM ROE is about 21.9%.

  • Valuation is expensive. TTM P/E is in the 70th percentile, above most peers.

  • Recent volatility is comparatively low. 60-day annualized volatility is in the 7th percentile. Average 20-day dollar volume is about $103.1M.

  • Signals are active now. Top-quintile 6-month momentum currently holds; the tables below show what followed in this stock’s own history.

Historical evidence

Signals active now

Each active condition is tested against this stock’s own history and benchmarked versus the S&P 500.

Top-quintile 6-month momentum

Active · now 83.16326530612244%

The stock ranks in the top 20% of the liquid US common-stock universe by 126-day adjusted return.

34 historical occurrences (since 2016-10-13)
Average forward return after Top-quintile 6-month momentum。20-day: Win 63.6%, Sample 33, Median +1.47%, Excess +0.15%, Beat mkt rate 51.5%；60-day: Win 51.6%, Sample 31, Median +0.34%, Excess +5.78%, Beat mkt rate 51.6%；120-day: Win 63.3%, Sample 30, Median +13.21%, Excess +16.33%, Beat mkt rate 66.7%

120 days after: historical avg +22.21%

20-day +1.75%
60-day +9.72%
120-day +22.21%
20-day
60-day
120-day
Win
63.6%
51.6%
63.3%
Sample
33
31
30
Median
+1.47%
+0.34%
+13.21%
Excess
+0.15%
+5.78%
+16.33%
Beat mkt rate
51.5%
51.6%
66.7%

Over 30 occurrences, 120-day forward avg gained 22.21%, beat the market by 16.33 pts; win rate 63.3%.

Valuation regime and forward returns

Daily TTM P/E is converted into an expanding own-history percentile, then grouped into five valuation regimes. Forward returns use adjusted prices over the next 240 trading days.

PE percentile bandSample days240-day avg returnMedianWin rateAvg excess (vs index)
0-20 0Insufficient data
20-40 66+45.9% +46.4% 100% +21.5%
40-60 You are here239+18.1% +14.1% 90.4% -2.7%
60-80 115+26.6% +32.2% 60% +8.6%
80-100 265+17% +5.3% 57.4% -0.5%

Quarterly EPS is aligned by SEC filing date before it is forward-filled to daily prices. The expanding percentile uses only information available up to each day.

Current TTM P/E is about 18.20, placing it in the 58.5 own-history percentile, inside the 40-60 bucket.

Valuation × momentum analogs

Each historical day is grouped by own-history P/E tercile and 60-day momentum direction, then tested for the next 120-trading-day adjusted return.

Valuation
Momentum
Cheap (own-history bottom third)
Middle
Expensive (own-history top third)
60-day momentum up
Insufficient data
(18d)
Now
+5.7%
Win rate 48.2% Excess -3.7%
195d
+7.7%
Win rate 70% Excess -0.6%
280d
60-day momentum down
+17.4%
Win rate 100% Excess +11.9%
81d
+12.8%
Win rate 77.6% Excess +0.7%
134d
+9.4%
Win rate 52.6% Excess -1.2%
97d

Currently in “Middle × 60-day momentum up”: across 195 historical days, 120-day forward avg gained 5.7%, win rate 48.2%, lagged the market by 3.7%.

Days = trading days in this bucket; returns use adjusted prices, ex-costs. 60-day momentum: direction of this stock's price over the past 60 trading days.

Market-wide momentum baseline

Across 98,045 liquid US common-stock samples, top-quintile 6-month momentum was followed by an average 60-trading-day return of +6.24%, a 58.1% positive-return rate, and +2.88 percentage points of average excess return versus the S&P 500.

Baseline: weekly samples since 2016 where a liquid US common stock ranked in the top quintile by 126-trading-day momentum. Forward return is 60 trading days; excess return is versus S&P 500 (^GSPC).

Signals not active now

Inactive signals still show the stock-specific historical forward-return distribution for context.

52-week adjusted-price high

Pending

Adjusted close first reaches a 252-trading-day high; repeated hits within 20 days count once.

20 times historically; 60-day forward avg +4.04%, win rate 47.4%, beating the market by +2.1 pts on average.

Filed revenue acceleration

Pending

TTM revenue growth is at least 10% and improved versus the prior filed quarter; event date is the SEC filing date.

9 times historically; 60-day forward avg +5.65%, win rate 55.6%, beating the market by +2.17 pts on average.

EPS surprise beat

Pending

Reported EPS beat consensus estimate by at least 5%; event date is the earnings-surprise timestamp.

30 times historically; 60-day forward avg +13.89%, win rate 73.1%, beating the market by +9.85 pts on average.

Method and limits

  • Returns use us_price:adj_close, adjusted for splits and dividends where available.
  • Excess returns use world_index:^GSPC as the S&P 500 benchmark proxy.
  • Quarterly fundamentals are aligned to SEC filing dates before daily valuation studies.
  • The promoted universe starts from active NYSE/NASDAQ common stocks, then applies price and dollar-volume gates.
  • Snapshot-only tables such as analyst consensus, DCF, us_ratios, and us_key_metrics are intentionally excluded from historical evidence.
  • Overlapping event windows are descriptive distributions, not independent samples.

This page is for historical data analysis and education only. It is not investment advice. Backtests and historical return distributions do not predict future performance; evaluate risk independently before trading.